Advanced search
Publication Cover
Hepatic Oncology Volume 5, 2018 - Issue 1
Submit an article Journal homepage
1,227
Views
3
CrossRef citations to date
0
Altmetric
Case Report

Development of shellfish allergy after exposure to dual immune checkpoint blockade

Zachary J Brown1 Gastrointestinal Malignancy Section, Thoracic & Gastrointestinal Oncology Branch, Center for Cancer Research,National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USACorrespondence[email protected]
View further author information
,
Bernd Heinrich1 Gastrointestinal Malignancy Section, Thoracic & Gastrointestinal Oncology Branch, Center for Cancer Research,National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USAView further author information
&
Tim F Greten1 Gastrointestinal Malignancy Section, Thoracic & Gastrointestinal Oncology Branch, Center for Cancer Research,National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USAView further author information
Article: HEP02 | Received 26 Sep 2017, Accepted 17 Jan 2018, Published online: 09 Feb 2018

References

  • Ryerson AB, Eheman CR, Altekruse SF et al. Annual report to the Nation on the status of cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer 122(9), 1312–1337 (2016).
  • Bruix J, Qin S, Merle P et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, Phase III trial. Lancet 389(10064), 56–66 (2017).
  • Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378–390 (2008).
  • Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 12(12), 681–700 (2015).
  • Michot JM, Bigenwald C, Champiat S et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer 54, 139–148 (2016).
  • Postow MA, Chesney J, Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372(21), 2006–2017 (2015).
  • Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J. Immunol. 192(12), 5451–5458 (2014).
  • Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PloS ONE 11(7), e0160221 (2016).
  • Maughan BL, Bailey E, Gill DM, Agarwal N. Incidence of immune-related adverse events with program death receptor-1- and program death receptor-1 ligand-directed therapies in genitourinary cancers. Front. Oncol. 7, 56 (2017).
  • Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy – immune checkpoint blockade and associated endocrinopathies. Nat. Rev. Endocrinol. 13(4), 195–207 (2017).
  • Chen TW, Razak AR, Bedard PL, Siu LL, Hansen AR. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann. Oncol. 26(9), 1824–1829 (2015).
  • Choyke PL, Miller DL, Lotze MT, Whiteis JM, Ebbitt B, Rosenberg SA. Delayed reactions to contrast media after interleukin-2 immunotherapy. Radiology 183(1), 111–114 (1992).
  • Zukiwski AA, David CL, Coan J, Wallace S, Gutterman JU, Mavligit GM. Increased incidence of hypersensitivity to iodine-containing radiographic contrast media after interleukin-2 administration. Cancer 65(7), 1521–1524 (1990).
  • Mall C, Sckisel GD, Proia DA et al. Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer. Oncoimmunology 5(2), e1075114 (2016).
  • Lopata AL, O’Hehir RE, Lehrer SB. Shellfish allergy. Clin. Exp. Allergy 40(6), 850–858 (2010).
  • El-Khoueiry AB, Sangro B, Yau T et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, Phase I/II dose escalation and expansion trial. Lancet 389(10088), 2492–2502 (2017).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.